Dec 20,2023

Efficacy and Safety of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Interventional Evidence

Traditional diabetes self-monitoring of blood glucose (SMBG) involves inconvenient finger pricks. Continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems offer CGM, enhancing type 2 diabetes (T2D) management with convenient, comprehensive data. This study aims to assess the benefits and potential harms of CGM and isCGM compared with usual care or SMBG in individuals with T2D.The researchers conducted a comprehensive search of MEDLINE, Embase, the Cochrane Library, Web of Science, and bibliographies up to August 2023. They included 26 RCTs (17 CGM and 9 isCGM) involving 2,783 patients with T2D. CGM reduced HbA1c and glycemic medication effect score, reduced user satisfaction, and increased the risk of adverse events. isCGM reduced HbA1c by ?0.31%, increased user satisfaction, improved CGM metrics, and increased the risk of adverse events. Accordingly, both CGM and isCGM demonstrated a reduction in HbA1c levels in individuals with T2D, and unlike CGM, isCGM use was associated with improved user satisfaction. The impact of these devices on body composition, blood pressure, and lipid levels remains unclear, while both CGM and isCGM use were associated with increased risk of adverse events.

CLINICAL STUDY

#cgm

#bgm

View Analyst & Ambassador Comments
Go to original news
Dec 18,2023

Medtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference

Medtronic announced it will participate in the 42nd annual J.P. Morgan healthcare conference on Monday, January 8, 2024. Geoff Martha, Medtronic chairman and chief executive officer, will make a formal presentation and answer questions on the company beginning at 9:00 a.m. PST (11:00 a.m. CST). Immediately following the presentation, Martha, Karen Parkhill, executive vice president and chief financial officer, and other company executive vice presidents will answer questions on the company.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Dec 18,2023

Advancing digital therapeutics and AI in 2023

Reflecting on the successful achievements accomplished by Liva Healthcare, the Company has shared that they have now supported more than 58,500 patients and participants who are living with obesity, prediabetes and type 2 diabetes, to lose weight and prevent, manage and reverse their condition. Liva is the digital provider for three NHS programmes: The Healthier You NHS National Diabetes Prevention Programme (NDPP), Digital Weight Management Programme (DWMP) and Type 2 Diabetes Path to Remission Programmes (T2DR). In October 2023, Liva Healthcare also reported early results from this last programme, showing patients losing significant weight and 70% of the patients after six months achieving HbA1C blood sugar levels within the non-diabetic range. In 2024, the company step the use of their AI and machine learning providing the coaches with automated transcribed summaries of patient activities, auto-generated journals of past activity, and assistance in generating the right personalised health content, behavioural nudges and notifications for patients to enhance their change journey. In October 2023, Liva was also selected by the NICE as one of the digital therapeutics platforms to offer hybrid weight-loss programmes in partnership with the NHS to help tackle the obesity crisis. In 2024, Liva is collaborating in a randomised controlled trial, testing an innovative maternal health intervention for lifestyle behaviour change during pregnancy and the first year after birth. The new study Bump2Baby and Me Project, reaches across four countries and targets pregnant women at high risk of gestational diabetes (GDM) and follows them until their baby’s first birthday. Lastly, Liva Healthcare was also announced to be part of the Lighthouse Consortium on Obesity Management (LightCOM), a three-year clinical trial bringing together researchers from the UK and Denmark to develop and test new obesity management programmes, backed by the Novo Nordisk Foundation.

#coaching

View Analyst & Ambassador Comments
Go to original news
Dec 18,2023

ABBOTT TO PRESENT AT J.P. MORGAN HEALTHCARE CONFERENCE

Abbott will present at the 42nd annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024. Robert B. Ford, chairman and chief executive officer, will present at 11 a.m. Central time. A live webcast of the presentation will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Dec 19,2023

Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference

DexCom announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 42nd annual J.P. Morgan Healthcare Conference on January 8, 2024. The live presentation is scheduled to begin at approximately 12:45 PM EST and will be concurrently webcast.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Dec 19,2023 TOP STORY

NICE announces final appraisal recommendations on hybrid closed-loop systems for Type 1 diabetes

A landmark announcement by the National Institute of Health Care and Excellence (NICE) outlines details of who will be offered hybrid closed-loop technology in England and Wales. Under the new recommendations, hybrid closed-loop has been recommended for adults living with type 1 diabetes who have an HbA1c of 58 mmol/mol (7.5%) or higher, or have disabling hypoglycaemia, despite best possible management with at least one of the following: Continuous subcutaneous insulin infusion (i.e. an insulin pump); Real-time continuous glucose monitoring (CGM); and Intermittently scanned continuous glucose monitoring (Flash). Hybrid closed-loop has also been recommended for children and young people (under 18 years old) living with type 1 diabetes and people living with type 1 diabetes who are pregnant or planning to become pregnant. The guidance goes on to say that hybrid closed-loop systems should only be used with the support of a trained multidisciplinary team experienced in insulin pumps and continuous glucose monitoring in type 1 diabetes. Guidance for NICE technical appraisals applies to England and Wales but can also be formally adopted in Northern Ireland, with work underway to start that process.

#closed loop

View Analyst & Ambassador Comments
Go to original news
Dec 13,2023 TOP STORY

Twin Health Secures $50M To Expand Its Groundbreaking Whole Body Digital Twin Technology And Service To Reverse Chronic Metabolic Disease

Twin Health, creators of the Whole Body Digital Twin™ service for reversing, improving, and preventing chronic metabolic diseases, announced securing $50 million in funding to continue expanding its groundbreaking technology and clinical service solutions for more members across the United States. The funding is led by Temasek, and the existing investors ICONIQ Growth, Sofina, Peak XV, and Helena also participated in this financing round. Twin Health has expanded its reach with strategic partners in the employer and health plan domains, covering over 4 million lives. Notable achievements include completing the world's first randomized controlled trial (RCT) for reversing chronic metabolic disease using digital twin technology. The one year results, recently published in the American Association of Clinical Endocrinology, showed a significant reduction in HbA1c in the intervention group (2.9% reduction from 9.0 to 6.1) and a significantly higher elimination of diabetes medications (elimination of 94% of type 2 diabetes medications in the intervention group).

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Dec 11,2023

Fruit Street Health Sues Sharecare for $25M

Fruit Street Health, a startup that delivers the CDC’s diabetes prevention program through group telehealth classes, filed a lawsuit against digital health company Sharecare on Friday. Fruit Street is suing Sharecare because it claims Sharecare violated the terms of their shared business agreement by rolling out its own version of the Fruit Street’s diabetes prevention program, which had been previously offered to Sharecare members. Sharecare told MedCity News that the complaint is without merit. The lawsuit, which was filed in the Superior Court of Fulton County in Georgia, seeks compensatory and punitive damages in excess of $25 million. The two healthcare companies began working together in 2018 when Sharecare began offering Fruit Street’s program on its platform. The lawsuit alleges that Sharecare engaged in internal misconduct and breached fiduciary duties it owed to Fruit Street when it launched a competing diabetes prevention program of its own in January and began promoting it in lieu of Fruit Street’s program.

#telehealth

#virtual care

#coaching

View Analyst & Ambassador Comments
Go to original news
Dec 13,2023

US employers hire virtual providers as weight-loss drug gatekeepers

U.S. employers facing surging costs from paying for Novo Nordisk’s Wegovy and similar obesity drugs are hiring virtual healthcare providers like Teladoc to implement weight-loss management programs, a dozen consultants, pharmacy benefit managers, analysts, and providers told Reuters. These programs may require diet and exercise before granting access to the medicines, and in some cases will become employees' sole covered option for medications like Wegovy and Eli Lilly’s rival therapy Zepbound, which have list prices of more than $1,000 a month. More than a quarter of 152 employers surveyed by the Business Group on Health said they would use virtual providers to oversee obesity drug prescriptions next year. Blue Cross Blue Shield of Michigan, a health insurer with more than 5 million members, said next year it will offer employer clients an option for patients to sign up for Teladoc’s weight management program that involves six months of diet and exercise before patients can get Wegovy or Zepbound. Richard Frank, an executive at virtual provider Vida Health, said his company planned to manage a weight-loss center of excellence for at least one of its clients next year.

#vitual care

#telehealth

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES